Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions

Research output: Contribution to journalJournal articleResearchpeer-review


  • Henning Kelbæk
  • Robert W Yeh
  • Thomas Engstrøm
  • Franz-Josef Neumann
  • Patrick W Serruys
  • Stephan Windecker
  • Jorge Belardi
  • Shubin Qiao
  • Bo Xu
  • Minglei Liu
  • Sigmund Silber
View graph of relations

AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.

METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).

CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.

Original languageEnglish
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Issue number16
Pages (from-to)1326-1332
Number of pages7
Publication statusPublished - 19 Mar 2021

    Research areas

  • Cardiovascular Agents, China/epidemiology, Coronary Artery Disease, Coronary Occlusion/surgery, Drug-Eluting Stents, Female, Humans, Male, Middle Aged, Myocardial Infarction, Percutaneous Coronary Intervention/adverse effects, Prosthesis Design, Sirolimus/analogs & derivatives, Time Factors, Treatment Outcome, Drug-eluting stent, Stable angina, Chronic coronary total occlusion, ACS/NSTE-ACS

ID: 59126040